文献速递肺结节与肺癌

肺癌纵隔淋巴结有创分期趋势及其对意外N2和生存的影响

Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer.
PubMed 文献 · Eur Respir J · 2021-04-01

cN1-3患者有创分期5年生存率44%对39%(P=0.12)。

要点

  • 有创纵隔分期比例从2005年26%升至2017年40%,超声内镜应用增加。
  • 意外N2发生率稳定在8.7%,未因微创分期增加而升高。
  • cN1-3患者有创分期可能带来生存获益(5年生存率44%对39%)。

核心结论

  • 荷兰可切除NSCLC患者有创纵隔分期显著增加,但意外N2未增加。
  • cN1-3患者进行有创分期可能带来总生存获益。

主要发现

  • 有创纵隔分期从2005年26%增至2017年40%(p<0.01)。
  • 超声内镜从2011年19%增至2017年32%(p<0.01),纵隔镜从24%降至21%(p=0.08)。
  • 意外N2发生率稳定在8.7%。
  • 5年总生存率:pN1为41%,单站意外N2为37%(p=0.18),多站意外N2为26%(p<0.01)。
  • cN1-3患者有创分期5年生存率44% vs 无有创分期39%(p=0.12)。

临床怎么用

  • 对可切除NSCLC患者,可优先采用超声内镜进行有创纵隔分期。
  • cN1-3患者应考虑有创纵隔分期以评估生存获益。

局限性

  • 为回顾性队列研究,可能存在选择偏倚。
  • 有创分期对cN1-3患者生存获益的P值为0.12,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Guidelines for invasive mediastinal nodal staging in resectable nonsmall cell lung cancer (NSCLC) have changed over the years. The aims of this study were to describe trends in invasive staging and unforeseen N2 (uN2) and to assess a potential effect on overall survival. METHODS: A nationwide Dutch cohort study included all clinical stage IA-IIIB NSCLC patients primarily treated by surgical resection between 2005 and 2017 (n=22 555). We assessed trends in invasive nodal staging (mediastinoscopy 2005-2017; endosonography 2011-2017), uN2 and overall survival and compared outcomes in the entire group and in clinical nodal stage (cN)1-3 patients with or without invasive staging. RESULTS: An overall increase in invasive nodal staging from 26% in 2005 to 40% in 2017 was found (p<0.01). Endosonography increased from 19% in 2011 to 32% in 2017 (p<0.01), while mediastinoscopy decreased from 24% in 2011 to 21% in 2017 (p=0.08). Despite these changes, uN2 was stable over the years at 8.7%. 5-year overall survival rate was 41% for pN1 compared to 37% in single node uN2 (p=0.18) and 26% with more than one node uN2 (p<0.01). 5-year overall survival rate of patients with cN1-3 with invasive staging was 44% versus 39% in patients without invasive staging (p=0.12). CONCLUSION: A significant increase in invasive mediastinal nodal staging in patients with resectable NSCLC was found between 2011 and 2017 in the Netherlands. Increasing use of less invasive endosonography prior to (or as a substitute for) surgical staging did not lead to more cases of uN2. Performance of invasive staging indicated a possible overall survival benefit in patients with cN1-3 disease.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Bousema JE, Aarts MJ, Dijkgraaf MGW, et al. Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer. Eur Respir J. 2021. PMID: 33008940. doi:10.1183/13993003.01549-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。